Arena Pharmaceuticals, Inc. Pushing Shorter Study of Rejected Diet Pill
Arena Pharmaceuticals plans to spend three months studying breast tumors in rats receiving large amounts of its experimental diet pill rather than the 12 months suggested by federal regulators, executives with the San Diego company said Tuesday.
"We have talked with the (Food and Drug Administration), and the discussion was just on the shorter study," said Jack Lief, Arena's president and chief executive officer, during a conference call with stock analysts after the company released first-quarter financial results.